Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor agonists reported to be potentially useful for the treatment of mood disorders.
Pheon Therapeutics Ltd. has patented antibody-drug conjugates, comprising an antibody targeting CDCP1 covalently linked to a cytotoxic drug through a linker, that are potentially useful for the treatment of cancer.
Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGKA) and/or diacylglycerol kinase ζ (DGKZ) inhibitors reported to be potentially useful for the treatment of cancer.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. has divulged tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 inhibitors that are potentially useful for the treatment of cancer.
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors potentially useful for the treatment of cancer, pain, fibrosis and inflammatory disorders.
Brown University, Florida Atlantic University and Florida International University have jointly identified new compounds potentially useful for the treatment of malaria.
Onkure Therapeutics Inc. has disclosed new benzopyridinones acting as phosphatidylinositol 3-kinase α (PI3Kα) mutant inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities, scoliosis and PIK3CA-related overgrowth spectrum (PROS).
RSS